Erasca Inc. Unveils Pipeline Targeting RAS/MAPK Pathway to Erase Cancer

Reuters11-13

Erasca Inc. Unveils Pipeline Targeting RAS/MAPK Pathway to Erase Cancer

Erasca Inc. has released a new corporate presentation detailing its progress in oncology drug development. The presentation highlights the company's industry-leading pipeline focused on shutting down the RAS/MAPK pathway, featuring candidates such as ERAS-0015, a pan-RAS molecular glue targeting RAS-mutated solid tumors, and ERAS-4001, a pan-KRAS inhibitor for KRAS-mutated solid tumors. Additional programs, including ERAS-007 and ERAS-601, are being evaluated in preclinical studies as potential combination therapies. Erasca reports a strong financial position with $362 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and outlines a cash runway into the second half of 2028. The company's leadership team and scientific advisory board include recognized experts in the field of cancer genetics and targeted therapy development. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583838745?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583838745","market":"us","top_or_hot":-1,"title":"Erasca Inc. Unveils Pipeline Targeting RAS/MAPK Pathway to Erase Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Erasca Inc. Unveils Pipeline Targeting RAS/MAPK Pathway to Erase Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Erasca Inc. has released a new corporate presentation detailing its progress in oncology drug development. The presentation highlights the company's industry-leading pipeline focused on shutting down the RAS/MAPK pathway, featuring candidates such as ERAS-0015, a pan-RAS molecular glue targeting RAS-mutated solid tumors, and ERAS-4001, a pan-KRAS inhibitor for KRAS-mutated solid tumors. Additional programs, including ERAS-007 and ERAS-601, are being evaluated in preclinical studies as potential combination therapies. Erasca reports a strong financial position with $362 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and outlines a cash runway into the second half of 2028. The company's leadership team and scientific advisory board include recognized experts in the field of cancer genetics and targeted therapy development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca Inc. Unveils Pipeline Targeting RAS/MAPK Pathway to Erase Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca Inc. Unveils Pipeline Targeting RAS/MAPK Pathway to Erase Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Erasca Inc. Unveils Pipeline Targeting RAS/MAPK Pathway to Erase Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Erasca Inc. has released a new corporate presentation detailing its progress in oncology drug development. The presentation highlights the company's industry-leading pipeline focused on shutting down the RAS/MAPK pathway, featuring candidates such as ERAS-0015, a pan-RAS molecular glue targeting RAS-mutated solid tumors, and ERAS-4001, a pan-KRAS inhibitor for KRAS-mutated solid tumors. Additional programs, including ERAS-007 and ERAS-601, are being evaluated in preclinical studies as potential combination therapies. Erasca reports a strong financial position with $362 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and outlines a cash runway into the second half of 2028. The company's leadership team and scientific advisory board include recognized experts in the field of cancer genetics and targeted therapy development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2dQVh5:1","article_id":"2583838745","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583838745","pubTimestamp":1762982271,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Erasca Inc. has released a new corporate presentation detailing its progress in oncology drug development. The presentation highlights the company's industry-leading pipeline focused on shutting down the RAS/MAPK pathway, featuring candidates such as ERAS-0015, a pan-RAS molecular glue targeting RAS-mutated solid tumors, and ERAS-4001, a pan-KRAS inhibitor for KRAS-mutated solid tumors. Additional programs, including ERAS-007 and ERAS-601, are being evaluated in preclinical studies as potential combination therapies. Erasca reports a strong financial position with $362 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and outlines a cash runway into the second half of 2028. The company's leadership team and scientific advisory board include recognized experts in the field of cancer genetics and targeted therapy development. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  usi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","ERAS":"Erasca, INC."},"translate_title":"Erasca Inc.推出靶向RAS/MAPK途径消除癌症的管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":0.9},"content_text":"Erasca Inc. Unveils Pipeline Targeting RAS/MAPK Pathway to Erase Cancer\n    \n\n        Erasca Inc. has released a new corporate presentation detailing its progress in oncology drug development. The presentation highlights the company's industry-leading pipeline focused on shutting down the RAS/MAPK pathway, featuring candidates such as ERAS-0015, a pan-RAS molecular glue targeting RAS-mutated solid tumors, and ERAS-4001, a pan-KRAS inhibitor for KRAS-mutated solid tumors. Additional programs, including ERAS-007 and ERAS-601, are being evaluated in preclinical studies as potential combination therapies. Erasca reports a strong financial position with $362 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and outlines a cash runway into the second half of 2028. The company's leadership team and scientific advisory board include recognized experts in the field of cancer genetics and targeted therapy development. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583838745","isCrawlerRequest":true}